Abstract:Abstract Background Glioblastoma multiforme (GBM), a lethal brain tumor, remains the most daunting challenge in cancer therapy. Overexpression and constitutive activation of PDGFs and PDGFRα are observed in most GBM; however, available inhibitors targeting isolated signaling pathways are minimally effective. Therefore, better understanding of crucial mechanisms underlying GBM is needed for developing more effective targeted therapies. Methods Target genes controlled by HIF1α in GBM were identified by analysis of TCGA database and by RNA-sequencing of GBM cells with HIF1α knockout by sgRNA-Cas9 method. Functional roles of HIF1α, PDGFs and PDGFRs were elucidated by loss- or gain-of-function assays or chemical inhibitors, and compared in response to oxygen tension. Pharmacological efficacy and gene expression in mice with intracranial xenografts of primary GBM were analyzed by bioluminescence imaging and immunofluorescence. Results HIF1α binds the PDGFD proximal promoter and PDGFRA intron enhancers in GBM cells under normoxia or mild-hypoxia to induce their expression and maintain constitutive activation of AKT signaling, which in turn increases HIF1α protein level and activity. Paradoxically, severe hypoxia abrogates PDGFRα expression despite enhancing HIF1α accumulation and corresponding PDGF-D expression. Knockout of HIF1A , PDGFD or PDGFRA in U251 cells inhibits cell growth and invasion in vitro and eradicates tumor growth in vivo. HIF1A knockdown in primary GBM extends survival of xenograft mice, whereas PDGFD overexpression in GL261 shortens survival. HIF1α inhibitor Echinomycin induces GBM cell apoptosis and effectively inhibits growth of GBM in vivo by simultaneously targeting HIF1α-PDGFD/PDGFRα-AKT feedforward pathway. Conclusions HIF1α orchestrates expression of PDGF-D and PDGFRα for constitutive activation of AKT pathway and is crucial for GBM malignancy. Therefore, therapies targeting HIF1α should provide an effective treatment for GBM.

Hypoxia-Induced Autophagy Is Involved in Radioresistance via HIF1A-Associated Beclin-1 in Glioblastoma Multiforme

SDC1-TGM2-FLOT1-BHMT complex determines radiosensitivity of glioblastoma by influencing the fusion of autophagosomes with lysosomes

Upregulated AHIF-mediated Radioresistance in Glioblastoma.

Induction Of Autophagy Promotes Differentiation Of Glioma-Initiating Cells And Their Radiosensitivity

The Role of Autophagy in Sensitizing Malignant Glioma Cells to Radiation Therapy

Autophagy Mediates Glucose Starvation-Induced Glioblastoma Cell Quiescence and Chemoresistance Through Coordinating Cell Metabolism, Cell Cycle, and Survival

Blockage of Autophagy in C6 Glioma Cells Enhanced Radiosensitivity Possibly by Attenuating DNA-PK-Dependent DSB Due to Limited Ku Nuclear Translocation and DNA Binding

The Role of Hypoxia and Cancer Stem Cells in Development of Glioblastoma

Autophagy Enhanced the Radioresistance of Non-Small Cell Lung Cancer by Regulating ROS Level under Hypoxia Condition

AHIF Promotes Glioblastoma Progression and Radioresistance Via Exosomes.

CircFOXO3 upregulation mediates the radioresistance of glioblastoma by affecting cellular metabolome

Autophagy is the main driver of radioresistance of HNSCC cells in mild hypoxia

The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin

Single-cell RNA sequencing identifies critical transcription factors of tumor cell invasion induced by hypoxia microenvironment in glioblastoma

Regulation of hypoxia-induced autophagy in glioblastoma involves ATG9A

FOXG1 Mediates the Radiosensitivity of Glioma Cells Through Regulation of Autophagy.

Suppression of autophagy augments the radiosensitizing effects of STAT3 inhibition on human glioma cells.

Advances in the Targeting of HIF-1α and Future Therapeutic Strategies for Glioblastoma Multiforme

Upregulation of DNA Metabolism-Related Genes Contributes to Radioresistance of Glioblastoma.

Silencing of FOXG1 confers radio-sensitivity through regulating autophagy in glioma cells

Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme